Brief: Actelion wins Swiss approval of uptravi for form of high blood pressure

Nippon Shinyaku

16/08/2016 06:00

Aug 16 (Reuters) - Actelion Ltd  ATLN.S  
    * Says receives Swissmedic approval for uptravi (selexipag) 
for treatment of pulmonary arterial hypertension 
    * Swissmedic has granted approval for orally active 
originally discovered and synthesized by Nippon Shinyaku, for 
patients with PAH in Switzerland 
 
Source text for Eikon:  ID:nHUG15BH1V  
Further company coverage:  ATLN.S  
 
 ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;))